U.S. Markets close in 1 hr 34 mins
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    49,371.11
    +899.67 (+1.86%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily pretreated colorectal cancer patients harboring a KRASG12C mutation.

  • Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients.

  • The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.

  • As of May 25, the response rate in the 45 evaluable patients who received adagrasib as monotherapy stood at 22%, including one unconfirmed partial response (PR) and a disease control rate (DCR) of 87%.

  • The median duration of response was 4.2 months, with the median progression-free survival (PFS) was 5.6 months.

  • Mirati also shared an update on patients who have received adagrasib in combination with Eli Lilly And Co's (NYSE: LLY) Erbitux (cetuximab).

  • The response rate in the 28 evaluable patients who received the combination was 43%, including two people with unconfirmed partial responses and a disease control rate of 100% at a median seven-month check-in.

  • After the July 9 data cutoff, follow-up scans confirmed one response, but the other patient progressed.

  • There were no deaths reported in either arm of the study, and the combination arm outperformed the solo drug arm in terms of Grade 3/4 side effects with rates of 16% and 30%, respectively.

  • Price Action: MRTX stock is down 3.19% at $168.50 during the premarket session on the last check Monday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.